PHAT Q2 2025 Earnings — Phathom Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

PHATPhathom Pharmaceuticals, Inc.

$891M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+439.4% YoY

Gross Profit

$34M87.2% margin

Operating Income

-$60M-151.7% margin

Net Income

-$76M-191.9% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

+38.5%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$63M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$250M

Total Liabilities

$656M

Stockholders' Equity

-$406M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$7M	+439.4%
Gross Profit	$34M	$6M	+479.4%
Operating Income	-$60M	-$77M	+22.5%
Net Income	-$76M	-$91M	+17.1%